Cidara Therapeutics’ (CDTX) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Cidara Therapeutics (NASDAQ:CDTX) in a research report report published on Tuesday, Benzinga reports.

Separately, HC Wainwright reaffirmed a buy rating and set a $120.00 target price on shares of Cidara Therapeutics in a research report on Monday, April 8th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Cidara Therapeutics presently has a consensus rating of Buy and an average target price of $71.25.

Cidara Therapeutics Stock Up 5.8 %

Shares of NASDAQ:CDTX opened at $13.00 on Tuesday. The firm has a market cap of $1.19 billion, a P/E ratio of -54.17 and a beta of 0.98. Cidara Therapeutics has a 12-month low of $10.00 and a 12-month high of $29.60. The business has a fifty day simple moving average of $15.37 and a 200 day simple moving average of $15.33.

Institutional Trading of Cidara Therapeutics

Large investors have recently made changes to their positions in the company. Flagship Harbor Advisors LLC acquired a new stake in shares of Cidara Therapeutics in the 3rd quarter valued at about $28,000. Pale Fire Capital SE acquired a new position in Cidara Therapeutics during the 3rd quarter valued at about $51,000. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in Cidara Therapeutics by 25.2% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 79,119 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 15,912 shares during the last quarter. 35.82% of the stock is currently owned by institutional investors and hedge funds.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.